Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advagraf-based immunosuppression with or without sirolimus after kidney transplantation
NL-OMON38063Phase 4Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in kidney transplant comparing Advagraf + sirolimus with Advagraf + mycophenolate mofetil (2 arms). Primary endpoint: Glomerular filtration rate by iohexol clearance at week 52. Started Sep 2011; status: active, not recruiting.
02
Drugs
tacrolimussirolimusmycophenolate mofetil
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON38063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38063.